Pharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks
If approved, deucrictibant will be the first oral bradykinin B2 receptor antagonist to tre
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.